Tier 3 — preclinical

Betaine alleviates nonalcoholic fatty liver disease (NAFLD) via a manner involving BHMT/FTO/m6A/ PGC1α signaling

Jiaqi Liu, Yuxi Liu, Yushi Chen, Youhua Liu, Chaoqun Huang, Yaojun Luo, Xinxia Wang
The Journal of nutritional biochemistry 2024 134:109738

Bibliography

PubMed
PMID 39154792
DOI
10.1016/j.jnutbio.2024.109738
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
Reported disclosure: The authors declare that there are no conflicts of interest.

Study snapshot

DesignExperimental animal and/or laboratory research
ModelExperimental mouse and cellular liver models
SampleExperiment-specific biological replicates and model groups; see original methods
InterventionBetaine exposure with BHMT/FTO-pathway experiments
DurationModel-specific laboratory protocols
EndpointsLiver lipids; RNA methylation; BHMT/FTO

What the study showed, in plain terms

Published in 2024, this source examined preclinical aging, brain and metabolic mechanisms. Design: Experimental animal and/or laboratory research. Sample/model: Experiment-specific biological replicates and model groups; see original methods. The exposure or intervention was Betaine exposure with BHMT/FTO-pathway experiments. Follow-up or treatment period: Model-specific laboratory protocols.

The authors proposed that BHMT, FTO and RNA methylation influence PGC1alpha expression and liver-lipid accumulation during betaine exposure.

Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • The authors proposed that BHMT, FTO and RNA methylation influence PGC1alpha expression and liver-lipid accumulation during betaine exposure.
  • The recorded outcome domains were Liver lipids; RNA methylation; BHMT/FTO.
  • The result applies to the tested exposure: Betaine exposure with BHMT/FTO-pathway experiments; Model-specific laboratory protocols.

What this study can and cannot tell us

  • Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
Manal F Abdelmalek et al. · Hepatology (Baltimore, Md.) · 2009
Tier 2
Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
Andrew S Lim et al. · Hepatology (Baltimore, Md.) · 2026
Tier 4
Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential
Tatjana Radosavljevic et al. · Antioxidants (Basel, Switzerland) · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 3
Systematic profiling reveals betaine as an exercise mimetic for geroprotection
Lingling Geng et al. · Cell · 2025
Tier 4
Betaine and aging: A narrative review of findings, possible mechanisms, research perspectives, and practical recommendations
Emilia Zawieja et al. · Ageing research reviews · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology